

**Louisiana Department of Health
Medicaid Pharmaceutical and Therapeutics Committee**

In-Person:

**628 North Fourth Street
Baton Rouge, LA
Bienville Building, Room #118**

Via Videoconferencing:

https://magellanhealth.zoom.us/webinar/register/WN_B8OKBzKUQuyjtjGZlurm1FA

November 4, 2022

9:00 AM

DRAFT

- I. Call to Order.....Ben Orlando
- II. Parliamentary BusinessBen Orlando
 - A. Introduction of Members/Roll Call
 - B. Election of Chairman and Co-Chairman
 - C. P & T Bylaws – Proposed Amendments
 - D. Approval of April 26, 2019 Meeting Minutes
 - E. May 6, 2022 Review Minutes
- III. Ethics Reminders.....Haley Williams
- IV. P & T Committee Review Virtual/In-Person Process.....Hind Douiki/Melwyn Wendt
- V. Reports.....Melwyn Wendt
 - A. PDL Reflecting Spring 2022 Recommendations
- VI. New Business.....Hind Douiki
 - A. Explanation of TOPS, Monographs and Cost Sheet
 - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony/Public Testimony
 - 1. Alzheimer’s Agents
 - 2. Anthelmintics
 - 3. Anti-Allergens, Oral
 - 4. Anticonvulsants
 - 5. Antidepressants, Other
 - 6. Antidepressants, SSRIs
 - 7. Antihistamines, Minimally Sedating
 - 8. Antihypertensives, Sympatholytics
 - 9. Antihyperuricemics
 - 10. Antiparkinson’s Agents
 - 11. Antipsoriatics, Oral
 - 12. Antipsoriatics, Topical
 - 13. Antipsychotics
 - 14. Anxiolytics
 - 15. Bile Salts
 - 16. Botulinum Toxins

17. Bronchodilators, Beta Agonist
18. Colony Stimulating Factors
19. COPD Agents
20. Cytokine and CAM Antagonists
21. Emollients
22. Enzyme Replacement, Gauchers Disease
23. Epinephrine, Self-Injected
24. Erythropoiesis Stimulating Proteins
25. Glucocorticoids, Inhaled
26. Glucocorticoids, Oral
27. Hemophilia Treatment
28. Histamine II Receptor Blocker
29. Idiopathic Pulmonary Fibrosis
30. Immune Globulins
31. Immunomodulators, Asthma
32. Immunomodulators, Atopic Dermatitis
33. Immunomodulators, Lupus
34. Immunomodulators, Topical
35. Intranasal Rhinitis Agents
36. Leukotriene Modifiers
37. Methotrexate
38. Movement Disorders
39. Neuropathic Pain
40. NSAIDs
41. Oncology Oral – Breast
42. Oncology Oral – Hematologic
43. Oncology Oral - Lung
44. Oncology Oral – Other
45. Oncology Oral – Prostate
46. Oncology Oral – Renal Cell
47. Oncology Oral - Skin
48. Ophthalmic, Antibiotic-Steroid Combinations
49. Ophthalmic Antibiotics
50. Ophthalmics for Allergic Conjunctivitis
51. Ophthalmics, Anti-Inflammatory
52. Ophthalmics, Anti-Inflammatory/ Immunomodulator
53. Ophthalmics, Cystinosis
54. Ophthalmics, Glaucoma Agents
55. Otic Anti-Infectives & Anesthetics
56. Otic Antibiotics
57. Progestational Agents
58. Sedative Hypnotics
59. Sickle Cell Anemia Treatments
60. Smoking Cessation
61. Steroids, Topical High
62. Steroids, Topical Low

- 63. Steroids, Topical Medium
- 64. Steroids, Topical Very High
- 65. Stimulants and Related Agents
- 66. Thrombopoiesis Stimulating Proteins

VII. New Single Drug Reviews.....Hind Douiki

- 67. Antibiotics, Vaginal – Xaciato™
- 68. Antifungals, Oral – Vivjoa™ Capsule
- 69. Calcium Channel Blockers – Norliqva®
- 70. GI Motility, Chronic – lbsrela®
- 71. HIV/AIDS – Triumeq® PD Tabs Susp
- 72. Hypoglycemics, Incretin Mimetics/Enhancers - Mounjaro®
- 73. Multiple Sclerosis Agents – Tascenso ODT
- 74. PAH Agents, Oral and Inhaled – Tyvaso DPI
- 75. Pediatric Vitamin Preparations – Multi-Vit-Flor Chew OTC
- 76. Pituitary Suppressive Agents, LHRH - Camcevi®
- 77. Skeletal Muscle Relaxants - Lyvispah®

VIII. Other Business

IX. Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

X. Next Meeting Date – Friday, May 5, 2023

XI. Public Testimony